🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thank you OncoDaily ASCO #asco25 for this amazing honor. Research never stops. Thanks to everyone from the IMDC and collaborators. UCalgaryMedicine Alberta Health Services @oncoalert

2nd Plenary #ASCO25: #NIVOPOSTOP Ph III, adj Nivolumab w/ ChemoXRT in high risk squamous cell head & neck ca after surgery. - 3yr DFS: 63.1% vs 52.5% (HR: 0.76). Benefit in all subgroups including CPS/PDL1 - Similar AEs in both arms - Is benefit driven by locations control?

#ASCO25: City of Hope’s Sumanta K. Pal, MD, FASCO breaks down IMmotion010 — a phase 3 #clinicaltrial aiming to uncover the mechanisms behind therapy resistance in patients with localized #kidneycancer.

Day 3 #ASCO25 highlights: 5 plenary studies 1. #ATOMIC: Adj Atezo in Stg III colon ca 2. #NIVOPOSTOP: Adj Nivo in high risk head & neck ca 3. #VERIFY: Rusfertide in PV 4. #SERENA6: Camizestrant in ESR1m breast Ca 5. #MATTERHORN: Peri/PostOP Durva in GEJ/Gastric ASCO 1/6

😇I'm thrilled and humbled to receive the Next Gen Disruptor Award. Heartfelt thanks HemOnc Today Healio! ASCO #ASCO25 #HealioInnovators 🙏I'm deeply grateful for the incredible mentors, sponsors, collaborators and friends who opened doors and supported me along the way.

Great poster session this morning with Nicolas Sayegh, MD highlighting work in #prostatecancer TMB & MSI-H w/ real world IO outcomes Foundation Medicine! Truly a star resident UTSW Simmons Cancer Center UTSW Internal Medicine co-mentored by me & Neeraj Agarwal, MD, FASCO. Look out for his fellowship apps this fall! #ASCO25

Very proud of our own Saad Atiq National Cancer Institute senior fellow presenting data on the Prevalence of Histology-Agnostic Biomarkers in Pure Squamous Cell Carcinomas of the #Bladder showing 1/3 of patients with TMB-High ASCO #ASCO25 Caris Life Sciences

One slide. One shift in standard of care: 🫁 Tarlatamab (anti-DLL3xCD3) improves OS in 2L SCLC. #ASCO25 #SCLC #oncology #immunotherapy @oncoalert ASCO IASLC Vivek Subbiah, MD LARVOL 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 Oncology Brothers TwoOncDocs Christian Rolfo

Great discussions @asco #ProstateCancer posters #ASCO25 #PSMA+ #BCR is an indolent process & pts do NOT require urgent therapy in most cases We should be ⚠️ cautious about over-treatment 🔗shorturl.at/NtxdF Trial continues to accrue National Cancer Institute clinicaltrials.gov/study/NCT05588…

Fantastic Women Leaders in Oncology event kicks off w Julie Gralow Rachna Shroff, MD, MS, FASCO #SonaliShah June Lanoue #ShubhGoel on panel moderated by Tania Small! Pearls for all of us to add to our day to day. ASCO #ASCO25

Words of wisdom from Clifford Hudis sharing his childhood stories & history of women in medicine — in his terms, with #AccidentalAllyship. ASCO is brighter and more inclusive for his leadership. Women Leaders in Oncology #ASCO25

Grateful for the opportunity to present our CLONEVO investigator-initiated trial (IIT) in bladder cancer at ASCO #ASCO2025. Here are some lessons I learned along the way: Investigator-initiated trials (IITs) are essential. IITs are clinical trials independently designed and led

This week on BT Tumor Board: Episode 17 focuses on #penilecancer diagnosis and treatment, featuring #UroOnc Dr. Charles Peyton, #RadOnc Dr. Juanita Crook, and #MedOnc Dr. Andrea Apolo. #ONC17 Andrea Apolo, M.D. UAB Urology GSRGT Education Committee ASCO open.spotify.com/episode/688Njo…

Dear Colleagues at #ASCO25 As ALWAYS, it is a pleasure for OncoAlert 🚨 to be around to capture yet another GREAT Uromigos discussion by Tom Powles 🇬🇧& Brian Rini, MD 🇺🇸 Here they are lakeside discussing ADC's in Advanced #BladderCancer Ping OncoAlert GU Faculty Sumanta K. Pal, MD, FASCO

Thank you Andrea Apolo, M.D. and Caris Life Sciences for the opportunity to lead this project!

As Zach Klaassen & Regina Barragan-Carrillo Instituto Nacional de Cancerología highlight, the GU oncology Early Thought Leaders meeting was truly a novel experience. Hosted by Andrea Apolo, M.D. Alan H Bryce Elizabeth Plimack MD & others, I loved the opportunity to sit 1:1 with lots of talented junior faculty & fellows in a

The most robust data post EVP in M1 bladder cancer by Michal Sternschuss MSKCC Carboplatin/gem was the commonest regimen #ASCO25 OncoAlert Results showed ⬆️ RRs than expected (50%) PFS =4.5 months & OS =11 months are good. 1st line gem/carbo OS was ~10 months previously?

Leaving Chicago & #ASCO25 with full heart. Reminded of our common purpose to #curecancer and make a difference for our patients. Thanks ASCO for a wonderful data, networking, & inspiration filled weekend!

Opening soon at the NIH!! E-VIRTUE, A Phase 2 Trial of Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors. Andrea Apolo, M.D. National Cancer Institute Nicholas Simon Dr. Andre R. Kydd Saad Atiq doi.org/10.1080/147966…